Pevonedistat - Takeda Oncology

Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Children's Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Takeda Oncology; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Myeloproliferative disorders
  • Phase I/II Mesothelioma
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 03 Apr 2018 Millennium Pharmaceuticals and Takeda plan a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) (IV) (NCT03486314)
  • 01 Apr 2018 OHSU Knight Cancer Institute and National Cancer Institute in collaboration plans a phase I trial for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma in USA , (NCT03479268)
  • 15 Mar 2018 Takeda plans a phase I trial for Acute myeloid leukaemia (Combination therapy) and Myelodysplastic syndromes (Combination therapy, Late-stage disease) in USA in September 2018 (NCT03459859)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top